insightSLICE

Myasthenia Gravis Treatment Market

Myasthenia Gravis Treatment Market - Global Market Share, Trends, Analysis and Forecasts, 2023 - 2032
Frequently asked questions about this report

The myasthenia gravis treatment market is estimated to exhibit a CAGR of 7% from 2023 to 2032.

Major players operating in the myasthenia gravis treatment market include Alexion Pharmaceutical Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies), CSL Behring, Grifols, S.A., Baxter International, Inc., Shire plc, Novartis AG, F. Hoffmann-La Roche AG, Takeda Pharmaceutical Company Limited and Valeant Pharmaceuticals International, Inc..

The myasthenia gravis treatment market was valued at US$ 1.2 billion in 2021.

Increasing awareness about rare diseases, rising investment in development of advanced neural therapies, and increasing investment in drug discovery are the key attributes fueling the growth of myasthenia gravis treatment market in future.

The base year considered in myasthenia gravis treatment market report is 2022.